Cantor Fitzgerald’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$410K Buy
+35,000
New +$572K ﹤0.01% 498
2025
Q2
– Sell
-25,000
Closed -$977K – 501
2025
Q1
$977K Buy
+25,000
New +$1.08M 0.02% 115

Other funds holding MLTX

Cantor Fitzgerald's MLTX Position: Q3 2026 in Review

Cantor Fitzgerald opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 35,000 shares worth $410K. The stake represents ﹤0.01% of the portfolio and ranks #498 among its holdings. This is a return to the name: Cantor Fitzgerald previously reported a position in MLTX as recently as Q1 2025.

Cantor Fitzgerald first reported a position in MLTX in Q1 2025 and has held it in 2 quarters since. The position peaked at $977K in Q1 2025. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

  • Cantor Fitzgerald held 35,000 shares of MoonLake Immunotherapeutics worth $410K as of Q3 2026.
  • MoonLake Immunotherapeutics was a new Cantor Fitzgerald position in Q3 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q3 2026, its #498 holding.
  • Cantor Fitzgerald first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 2 quarters since.
  • Cantor Fitzgerald's MoonLake Immunotherapeutics position peaked at $977K in Q1 2025.
  • 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Cantor Fitzgerald's 13F filing for Q3 2026, filed 16 Nov 2026.